MA45714A - Activateurs de glucokinase et leurs procédés d'utilisation - Google Patents
Activateurs de glucokinase et leurs procédés d'utilisationInfo
- Publication number
- MA45714A MA45714A MA045714A MA45714A MA45714A MA 45714 A MA45714 A MA 45714A MA 045714 A MA045714 A MA 045714A MA 45714 A MA45714 A MA 45714A MA 45714 A MA45714 A MA 45714A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- glucokinase activators
- glucokinase
- activators
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title 1
- 108010021582 Glucokinase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365520P | 2016-07-22 | 2016-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45714A true MA45714A (fr) | 2019-05-29 |
Family
ID=59501613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045714A MA45714A (fr) | 2016-07-22 | 2017-07-21 | Activateurs de glucokinase et leurs procédés d'utilisation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10604541B2 (fr) |
| EP (1) | EP3487862A1 (fr) |
| JP (1) | JP7072557B2 (fr) |
| KR (1) | KR102513342B1 (fr) |
| CN (1) | CN109715637B (fr) |
| MA (1) | MA45714A (fr) |
| WO (1) | WO2018017910A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121263182A (zh) * | 2023-06-06 | 2026-01-02 | 华领医药技术(上海)有限公司 | 用于认知障碍和神经退行性疾病的葡萄糖激酶激活剂 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594113A (en) | 1988-06-23 | 1997-01-14 | Associates Of Cape Cod, Inc. | Endotoxin binding and neutralizing protein and uses thereof |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| WO1997012613A1 (fr) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Procede de traitement et de prevention des inflammations et de l'atherosclerose |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| PT1094816E (pt) | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| KR20020079988A (ko) | 2000-03-08 | 2002-10-21 | 메타베이시스 테라퓨틱스, 인크. | 신규한 아릴 프럭토스-1,6-비스포스파타제 억제제 |
| AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| WO2005025504A2 (fr) | 2003-09-12 | 2005-03-24 | Kemia, Inc. | Modulateurs de l'activite de la calcitonine et de l'amyline |
| PL2060266T3 (pl) | 2004-03-17 | 2012-01-31 | 7Tm Pharma As | Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych |
| PT1756096E (pt) | 2004-05-03 | 2009-10-16 | Hoffmann La Roche | Derivados de indolilo como moduladores do receptor x do fígado |
| JP2008502658A (ja) | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| CN101490064B (zh) * | 2006-07-06 | 2012-10-10 | 百时美施贵宝公司 | 新颖葡萄糖激酶活化剂及其使用方法 |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| GB0619325D0 (en) | 2006-09-30 | 2006-11-08 | Univ Strathclyde | New compounds |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| WO2008154563A1 (fr) | 2007-06-11 | 2008-12-18 | Bristol-Myers Squibb Company | Activateurs de la glucokinase de type phénylamide à substitution 1,3 hydroxy |
| CN101808995A (zh) | 2007-07-27 | 2010-08-18 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
| MX2010001784A (es) | 2007-08-13 | 2010-03-15 | Metabasis Therapeutics Inc | Activadores novedosos de la glucocinasa. |
| AR068540A1 (es) | 2007-09-28 | 2009-11-18 | Merck & Co Inc | Metodos de produccion de un derivado de pirazol-3-il-benzamida. |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| PE20110303A1 (es) | 2008-09-11 | 2011-05-21 | Pfizer | Derivados de heteroaril acetamidas como activadores de glucoquinasa |
| WO2010029300A1 (fr) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Composés bis-aromatiques pour utilisation dans le traitement de l’inflammation |
| WO2010107610A1 (fr) | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Méthode de traitement du diabète et des états pathologiques correspondants par thérapie combinatoire et compositions contenant de tels composés |
| US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
| WO2011130459A1 (fr) * | 2010-04-14 | 2011-10-20 | Bristol-Myers Squibb Company | Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US20130197229A1 (en) | 2010-10-13 | 2013-08-01 | Christopher Matthews | Method of making azaindazole derivatives |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| EP3191453B1 (fr) | 2014-09-09 | 2019-10-23 | Bristol-Myers Squibb Company | Modulateurs des récepteurs gpr120 à base d'acide phényl-(aza)cycloalkylcarboxylique |
-
2017
- 2017-07-21 MA MA045714A patent/MA45714A/fr unknown
- 2017-07-21 KR KR1020197004835A patent/KR102513342B1/ko active Active
- 2017-07-21 JP JP2019503225A patent/JP7072557B2/ja active Active
- 2017-07-21 WO PCT/US2017/043199 patent/WO2018017910A1/fr not_active Ceased
- 2017-07-21 CN CN201780057682.1A patent/CN109715637B/zh active Active
- 2017-07-21 US US16/318,173 patent/US10604541B2/en active Active
- 2017-07-21 EP EP17746324.7A patent/EP3487862A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP7072557B2 (ja) | 2022-05-20 |
| KR20190033571A (ko) | 2019-03-29 |
| US20190233449A1 (en) | 2019-08-01 |
| WO2018017910A1 (fr) | 2018-01-25 |
| CN109715637A (zh) | 2019-05-03 |
| CN109715637B (zh) | 2022-04-05 |
| JP2019523253A (ja) | 2019-08-22 |
| KR102513342B1 (ko) | 2023-03-22 |
| EP3487862A1 (fr) | 2019-05-29 |
| US10604541B2 (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3436048A4 (fr) | Néoantigènes et leurs procédés d'utilisation | |
| EP3684364A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3510040A4 (fr) | Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation | |
| EP3390624A4 (fr) | Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation | |
| EP3298168A4 (fr) | Agents réducteurs stabilisés et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
| EP3504213A4 (fr) | Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3319610A4 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3429635A4 (fr) | Composés anti-crispr et leurs procédés d'utilisation | |
| EP3416634A4 (fr) | Agents immunomodulateurs et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3319612A4 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3377612A4 (fr) | Expression fonctionnelle de monooxygénases et procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| EP3394065A4 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés | |
| EP3436030A4 (fr) | Récepteurs chimériques et leurs procédés d'utilisation | |
| EP3303634A4 (fr) | Variants de cas9 et procédés d'utilisation associés | |
| EP3435956A4 (fr) | Compositions photo-stabilisées et leurs procédés d'utilisation | |
| EP3368538A4 (fr) | Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| EP3352774A4 (fr) | Compositions de flavonoïdes et procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| EP3307762A4 (fr) | Variants de cas9 rapporteurs et leurs procédés d'utilisation |